PMID- 36863950
OWN - NLM
STAT- MEDLINE
DCOM- 20230314
LR  - 20230314
IS  - 1880-0920 (Electronic)
IS  - 1347-4367 (Linking)
VI  - 49
DP  - 2023 Apr
TI  - Validation of a genotyping technique for a surrogate marker of HLA-B( *)58:01 for 
      allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in 
      the Japanese population.
PG  - 100495
LID - S1347-4367(23)00007-1 [pii]
LID - 10.1016/j.dmpk.2023.100495 [doi]
AB  - Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare but 
      severe cutaneous adverse drug reactions. Certain human leukocyte antigen (HLA) 
      types have been associated with SJS/TEN onset, e.g., HLA-B( *)58:01 with 
      allopurinol-induced SJS/TEN, but HLA typing is time-consuming and expensive; 
      thus, it is not commonly used in clinical situations. In the previous work, we 
      demonstrated that the single-nucleotide polymorphisms (SNP) rs9263726 was in 
      absolute linkage disequilibrium with HLA-B( *)58:01 in the Japanese population, 
      and can be used as a surrogate marker for the HLA. Here, we developed a new 
      genotyping method for the surrogate SNP using the single-stranded tag 
      hybridization chromatographic printed-array strip (STH-PAS) technique and 
      performed an analytical validation. The results of genotyping rs9263726 using 
      STH-PAS correlated well with those obtained using the TaqMan SNP Genotyping Assay 
      for 15 HLA-B( *)58:01-positive and 13 HLA-B( *)58:01-negative patients (analytical 
      sensitivity and specificity were both 100%). Additionally, at least 1.11 ng of 
      genomic DNA was sufficient to digitally and manually detect positive signals on 
      the strip. Robustness studies showed that the annealing temperature (66  degrees C) was 
      the most important condition related to reliable results. Collectively, we 
      developed an STH-PAS method that can rapidly and easily detect rs9263726 for 
      predicting SJS/TEN onset.
CI  - Copyright (c) 2023 The Japanese Society for the Study of Xenobiotics. Published by 
      Elsevier Ltd. All rights reserved.
FAU - Tsukagoshi, Eri
AU  - Tsukagoshi E
AD  - Division of Medicinal Safety Science, National Institute of Health Sciences, 
      Kawasaki, 210-9501, Japan.
FAU - Nakamura, Ryosuke
AU  - Nakamura R
AD  - Division of Medicinal Safety Science, National Institute of Health Sciences, 
      Kawasaki, 210-9501, Japan. Electronic address: ryosnak@nihs.go.jp.
FAU - Tanaka, Yoichi
AU  - Tanaka Y
AD  - Division of Medicinal Safety Science, National Institute of Health Sciences, 
      Kawasaki, 210-9501, Japan.
FAU - Maekawa, Keiko
AU  - Maekawa K
AD  - Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Doshisha 
      Women's College of Liberal Arts, Kyotanabe, 610-0395, Japan.
FAU - Hiratsuka, Masahiro
AU  - Hiratsuka M
AD  - Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of 
      Pharmaceutical Sciences, Tohoku University, Sendai, 980-8578, Japan; Research 
      Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai, 
      980-8573, Japan; Tohoku Medical Megabank Organization, Tohoku University, Sendai, 
      980-8573, Japan; Department of Pharmaceutical Sciences, Tohoku University 
      Hospital, Sendai, 980-8574, Japan.
FAU - Asada, Hideo
AU  - Asada H
AD  - Department of Dermatology, School of Medicine, Nara Medical University, 
      Kashihara, 634-8522, Japan.
FAU - Saito, Yoshiro
AU  - Saito Y
AD  - Division of Medicinal Safety Science, National Institute of Health Sciences, 
      Kawasaki, 210-9501, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230208
PL  - England
TA  - Drug Metab Pharmacokinet
JT  - Drug metabolism and pharmacokinetics
JID - 101164773
RN  - 63CZ7GJN5I (Allopurinol)
RN  - 0 (HLA-B Antigens)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - *Allopurinol
MH  - *Stevens-Johnson Syndrome/genetics
MH  - Genotyping Techniques
MH  - Genotype
MH  - East Asian People
MH  - HLA-B Antigens/genetics
MH  - Biomarkers
OTO - NOTNLM
OT  - Allopurinol
OT  - Human leukocyte antigen
OT  - Screening test
OT  - Single-nucleotide polymorphism
OT  - Stevens-Johnson syndrome
OT  - Toxic epidermal necrolysis
COIS- Declaration of competing interest The authors declare that the research was 
      conducted in the absence of any commercial or financial relationships that could 
      be construed as a potential conflict of interest.
EDAT- 2023/03/03 06:00
MHDA- 2023/03/15 06:00
CRDT- 2023/03/02 22:05
PHST- 2022/11/18 00:00 [received]
PHST- 2023/02/02 00:00 [revised]
PHST- 2023/02/06 00:00 [accepted]
PHST- 2023/03/03 06:00 [pubmed]
PHST- 2023/03/15 06:00 [medline]
PHST- 2023/03/02 22:05 [entrez]
AID - S1347-4367(23)00007-1 [pii]
AID - 10.1016/j.dmpk.2023.100495 [doi]
PST - ppublish
SO  - Drug Metab Pharmacokinet. 2023 Apr;49:100495. doi: 10.1016/j.dmpk.2023.100495. 
      Epub 2023 Feb 8.